Pfizer’s hopes for cholesterol blockbuster dashed
Sales of cancer drug Ibrance also fall short of expectations.
X
Pfizer’s hopes for cholesterol blockbuster dashed
https://pharmaphorum.com/news/pfizers-hopes-cholesterol-blockbuster-dashed/
Pfizer
Novartis’ LEE011 on fast track to challenge Ibrance
US regulator grants fast review for breast cancer drug.
Education is key to US biosimilar success – Pfizer
Pfizer taking on J&J’s blockbuster Remicade.
Debiopharm teams up with Merck KGaA and Pfizer in lung cancer
Swiss biotech looks to combine small molecule drug with immunotherapy.
J&J says ready to fend off Remicade competitor
Pfizer’s rival launch should be considered “at risk”, says J&J
Pfizer set for US launch of Remicade biosimilar
Pfizer gearing up for US launch late next month.
Pfizer’s Lyrica patent appeal fails in UK
Generics firms free to exploit gap in Pfizer’s patent defences.
Pfizer finally decides not to split up company
Company will remain as one, but Read keeps his options open
Pfizer’s breast cancer drug step closer to EU approval
Ibrance is already Pfizer’s top oncology product.